InsidersTradesSigma
Simulations Plus, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Simulations Plus, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Simulations Plus, Inc. has recorded 181 reports. Market capitalisation: €370.9m. The latest transaction was filed on 8 July 2026 (Cession). Among the most active insiders: WOLTOSZ WALTER S. All data is accessible without an account.
181
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€24m
68 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Simulations Plus, Inc. Hold (neutral), based on 2 analysts. Average price target: US$17.25.
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,736 of 26,212 companies
37.2
score / 100
Value29
Quality45
FCF yld3.9%
Earn yld-17%
EV/EBITDA25.3x
ROE-39%
Gross mgn58%
Net mgn-82%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations181 total
1,000 shares@ US$18.360.0049% mcap2.2% of flowCommon StockSEC:0001544167-26-000011:0
4,177 shares@ US$18.440.021% mcap0.2% of flowCommon StockSEC:0001222526-26-000012:0
1,050 sharesCommon StockSEC:0001899390-26-000006:0
1,050 sharesCommon StockSEC:0001899390-26-000006:1
1,000 shares@ US$16.500.0039% mcap2.0% of flowCommon StockSEC:0001544167-26-000008:0
1,000 shares@ US$10.050.0030% mcap50.0% of flowCommon StockSEC:0001899390-26-000004:0
1,000 shares@ US$14.980.0045% mcap26.5% of flowCommon StockSEC:0001544167-26-000006:0
15,000 shares@ US$15.130.068% mcap1.7% of flowCommon StockSEC:0001222526-26-000007:0
2,117 shares0Common StockSEC:0001899498-26-000004:0
2,117 shares0Common StockSEC:0001627832-26-000007:0
2,117 shares0Common StockSEC:0001134615-26-000004:0
2,117 shares0Common StockSEC:0001222526-26-000005:0
1,000 shares@ US$13.370.0040% mcap23.5% of flowCommon StockSEC:0001544167-26-000004:0
866 shares@ US$16.910.0044% mcap27.3% of flowCommon StockSEC:0001774849-25-000008:0
1,771 shares0Common StockSEC:0001774849-25-000006:0
1,771 shares0Common StockSEC:0001899498-25-000003:0
1,771 shares0Common StockSEC:0001627832-25-000004:0
1,771 shares0Common StockSEC:0001222526-25-000008:0
1,771 shares0Common StockSEC:0001134615-25-000004:0
20,000 shares@ US$15.390.092% mcap2.4% of flowCommon StockSEC:0001222526-25-000006:0
867 shares@ US$14.100.0037% mcap22.7% of flowCommon StockSEC:0001774849-25-000004:0
2,074 shares0Common StockSEC:0001628280-25-037453:0
2,074 shares0Common StockSEC:0001628280-25-037449:0
2,074 shares0Common StockSEC:0001628280-25-037446:0
2,074 shares0Common StockSEC:0001628280-25-037442:0
25 of 181 declarations
About Simulations Plus, Inc.
Simulations Plus, Inc. (NASDAQ: SLP) is a U.S.-based specialist in modeling and simulation software and scientific consulting for the pharmaceutical and biotechnology industries. Listed on the U.S. NASDAQ market, the company is headquartered in Lancaster, California, United States. It was founded in 1996 and has evolved into a recognized provider of decision-support tools used in drug discovery, development, and optimization. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai)) The business model is built on two main pillars: software and consulting services. On the software side, Simulations Plus markets best-known products such as GastroPlus, a widely used platform for simulating absorption, pharmacokinetics, and pharmacodynamics, along with additional tools for simulation and molecular-property prediction. The company also emphasizes capabilities in cheminformatics, biosimulation, simulation-enabled intelligence, clinical operations technology, and medical communications. ([stockanalysis.com](https://stockanalysis.com/stocks/slp/company/?utm_source=openai)) Its competitive position comes from a fairly uncommon combination: an established scientific software base, regulatory and domain expertise, and consulting services that support pharmaceutical clients across the development lifecycle. In a market where faster development, lower R&D costs, and better trial efficiency are increasingly important, this offering addresses a structural need. The company serves an international customer base, and its annual reporting has referenced independent distributors in Japan, China, India, South Korea, and Brazil, underscoring a commercial footprint beyond North America. ([fintel.io](https://fintel.io/doc/sec-simulations-plus-inc-1023459-10k-2024-october-30-20026-896?utm_source=openai)) Recent milestones highlight the company’s continued relevance for investors following specialized healthcare software names. In 2025, Simulations Plus released quarterly earnings updates and guidance revisions, keeping the stock on the radar of investors looking at niche healthcare technology and small-cap software companies. Management also described the company as a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications, while providing fiscal 2026 outlook commentary. In addition, Simulations Plus announced an investment in Nurocor, a clinical development technology company, suggesting a strategy to broaden its solution ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1023459/000102345925000051/pressrelease10222025.htm?utm_source=openai)) For French-speaking investors, Simulations Plus is best viewed as a specialized science-and-software name with exposure to global pharma innovation, a clear U.S. NASDAQ listing, and a differentiated niche positioning supported by recurring client relationships and mission-critical tools.
